ZLAB

Zai Lab Ltd

Nasdaq · CIK 1704292

Last close24.33
Daily change-1.17 (-4.59%)
10 Years gain-12.89%
Dividends TTM0
Dividend yield0.00%

Fundamental Analysis

ZLAB · STANDARD

SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231

Screener
Fundamental
59.5
Momentum
99.5
Acceleration
96.5
Confidence
90.0
Annual Revenue8
Quarterly Revenue23
Annual CFO8
Balance SheetAvailable
RankingEligible

Score Breakdown

Growth19.9 / 25
Quality15.8 / 25
Capital Efficiency3.5 / 20
Balance Sheet15.0 / 15
Shareholder Economics2.4 / 10
Forward Indicators0.0 / 5

Signals

Operating leverageOperating margin improved by 9.91 percentage points.
ROIC expansionROIC improved by 8.3713 percentage points.
Net debt reductionNet debt declined versus the comparison period.

Warnings

Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 4.9709 percentage points.

Key Metrics

Revenue Growth TTM7.85%OK
Revenue CAGR 3Y29.06%OK
Gross Margin58.6%OK
Operating Margin-58.62%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-32.54%OK
Incremental Operating Margin 3Y94.4%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.34%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL

Financial History

PeriodRevenueGross ProfitOperating IncomeCFOFCFGross MarginOp MarginFCF MarginROICShares
2025 FY Dec 31, 2025$457.18M$266.66M-$229.43M-$150.79M-$158.89M58.33%-50.18%-34.75%-85.62%1.1B
2025 FY Dec 31, 2024$397.61M$250.50M-$282.12M-$214.87M-$220.53M63%-70.95%-55.46%-244.1%989.48M
2025 FY Dec 31, 2023$266.72M$180.90M-$366.57M-$198.18M-$205.39M67.83%-137.44%-77.01%-2,161.78%966.39M
2024 FY Dec 31, 2022$212.67M$141.02M-$404.36M-$367.64M-$392.23M66.31%-190.13%-184.43%-8,005.06%958.07M
2023 FY Dec 31, 2021$144.11M$91.87M-$700.06M-$549.23M-$567.53M63.75%-485.8%-393.83%n/a929.92M

Formula Trace

MetricValueFormulaStatusSource
Revenue TTM$425.75Msum latest 4 fiscal quarters RevenueOK0001628280-26-053793, 0001704292-25-000024
Revenue Growth TTM7.85%Revenue_TTM / Revenue_TTM_1Y_ago - 1OK0001628280-26-053793, 0001704292-25-000024
Revenue CAGR 3Y29.06%(Revenue_current / Revenue_3Y_ago)^(1/3) - 1OK0001704292-26-000015
Revenue CAGR 5Y56.33%(Revenue_current / Revenue_5Y_ago)^(1/5) - 1OK0001704292-26-000015
Gross Profit CAGR 3Y23.66%(GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1OK0001704292-26-000015
Operating Income Growthn/aOperatingIncome_current / OperatingIncome_prior_year - 1INSUFFICIENT_HISTORY0001628280-26-053793, 0001704292-25-000024
FCF Growthn/aFCF_current / FCF_prior_year - 1INSUFFICIENT_HISTORYderived
Revenue Growth Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Gross Profit Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Operating Income Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
FCF Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Gross Margin58.6%Gross Profit / RevenueOK0001628280-26-053793, 0001704292-25-000024
Operating Margin-58.62%Operating Income / RevenueOK0001628280-26-053793, 0001704292-25-000024
ROIC-32.54%NOPAT / Average Invested CapitalOK0001628280-26-053793, 0001704292-25-000024
Net Debt / CFOn/aNet Debt / CFONOT_MEANINGFUL0001628280-26-053793
Current Ratio2.13xCurrent Assets / Current LiabilitiesOKderived
Cash / Debt2.59x(Cash + Short-term Investments) / Total DebtOK0001628280-26-053793
Revenue per Diluted Share$0.38Revenue / Diluted SharesOK0001628280-26-053793, 0001704292-25-000024